Будь ласка, використовуйте цей ідентифікатор, щоб цитувати або посилатися на цей матеріал:
http://repo.knmu.edu.ua/handle/123456789/7763
Назва: | Randomized, double-blind, controlled study of glycerol phenylbutyrate in hepatic encephalopathy |
Автори: | Rockey, Don Vierling, John Mantry, Parvez Ghabril, Marwan Brown, Robert Alexeeva, Olga Zupanets, Igor Grinevich, Vladimir Baranovsky, Andrey Dudar, Larysa Fadieienko, Galyna Kharchenko, Nataliya Klaryts’ka, Iryna Morozov, Vyacheslav Grewal, Priya McCashland, Timothy Reddy, Gautham Reddy, Rajender Syplyviy, Vasyl Bass, Nathan Dickinson, Klara Norris, Catherine Coakley, Dion Mokhtarani, Masoud Scharschmidt, Bruce |
Теми: | liver diseases encefalopathy clinical trials glycerol phenylbutyrate |
Дата публікації: | бер-2014 |
Бібліографічний опис: | Randomized, double-blind, controlled study of glycerol phenylbutyrate in hepatic encephalopathy / D. Rockey, J. Vierling, P. Mantry, M. Ghabril, R. S. Brown, O. Alexeeva, I. A. Zupanets, V. Grinevich, A. Baranovsky, L. Dudar, G. Fadieienko, N. Kharchenko, I. Klaryts’ka, V. Morozov, P. Grewal, T. McCashland, K. G. Reddy, K. Rajender Reddy, V. Syplyviy, N. M. Bass, K. Dickinson, C. Norris, D. Coakley, M. Mokhtarani, B. F. Scharschmidt // Hepatology. – 2014. – Vol. 54, N 3. – P. 1073–1083. |
Короткий огляд (реферат): | Glycerol phenylbutyrate (GPB) lowers ammonia by providing an alternate pathway to urea for waste nitrogen excretion in the form of phenylacetyl glutamine, which is excreted in urine. This randomized, double-blind, placebo-controlled phase II trial enrolled 178 patients with cirrhosis, including 59 already taking rifaximin, who had experienced two or more hepatic encephalopathy (HE) events in the previous 6 months. The primary endpoint was the proportion of patients with HE events. Other endpoints included the time to first event, total number of events, HE hospitalizations, symptomatic days, and safety. GPB, at 6 mL orally twice-daily, significantly reduced the proportion of patients who experienced an HE event (21% versus 36%; P=0.02), time to first event (hazard ratio [HR]=0.56; P<0.05), as well as total events (35 versus 57; P=0.04), and was associated with fewer HE hospitalizations (13 versus 25; P=0.06). Among patients not on rifaximin at enrollment, GPB reduced the proportion of patients with an HE event (10% versus 32%; P<0.01), time to first event (HR=0.29; P<0.01), and total events (7 versus 31; P<0.01). Plasma ammonia was significantly lower in patients on GPB and correlated with HE events when measured either at baseline or during the study. A similar proportion of patients in the GPB (79%) and placebo groups (76%) experienced adverse events. |
URI (Уніфікований ідентифікатор ресурсу): | https://repo.knmu.edu.ua/handle/123456789/7763 |
Розташовується у зібраннях: | Наукові праці. Кафедра загальної хірургії |
Файли цього матеріалу:
Файл | Опис | Розмір | Формат | |
---|---|---|---|---|
hep26611.pdf | 665,69 kB | Adobe PDF | Переглянути/відкрити |
Усі матеріали в архіві електронних ресурсів захищені авторським правом, всі права збережені.